Physician profile

Bashar Alkabbani

Dentist · Edina, MN

NPI 1790967958

$2,736.57

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$48.09
Entertainment$15.57

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Patterson Companies, INC. $750.00 2019
Sirona Dental, INC. $750.00 2019
Benco Dental Supply Co. $698.45 2021
Straumann USA LLC $330.62 2020-2023
Biolase, INC. $109.02 2019
Align Technology, INC. $36.16 2021
Gc America INC. $20.09 2024 Gc Initial, G-Cem, G-Aenial
Tulsa Dental Products LLC $15.84 2019
Coltene Whaledent INC. $15.57 2024
Dentsply Sirona INC $10.82 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bashar Alkabbani

$2,736.57

in general payments reported 2019-2025

Years
2019-2024
Top company
Patterson Companies, INC.

https://glasscript.com/doctor/1211413/bashar-alkabbani

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.